BACKGROUND Liquid biopsies that are based on analysis of cell-free DNA from plasma
offer diagnostic information that is otherwise accessible conventionally through invasive …

Precision oncology seeks to leverage molecular information about cancer to improve patient
outcomes. Tissue biopsy samples are widely used to characterize tumours but are limited by …

Current evidence suggests that plasma cell-free DNA (cfDNA) is fragmented around a mode
of 166 bp. Data supporting this view has been mainly acquired through the analysis of …

Precision medicine refers to the choosing of targeted therapies based on genetic data. Due
to the increasing availability of data from large-scale tumor genome sequencing projects …

Cell-free DNA (cfDNA) has pioneered the development of noninvasive prenatal testing and
liquid biopsy, its emerging applications include organ transplantation, autoimmune …

Background Analysis of cell-free DNA (cfDNA) is promising for broad applications in clinical
settings, but with significant bias towards late-stage cancers. Although recent studies have …

Background Noninvasive prenatal screening (NIPS) based on cell-free fetal DNA (cffDNA)
has rapidly been applied into clinic. However, the reliability of this method largely depends …

Cell‐free fetal DNA analysis has an established role in prenatal assessments. It serves as a
source of fetal genetic material that is accessible non‐invasively from maternal blood …

Introductory paragraph Non-invasive analysis of cancer genomes using cell-free circulating
tumour DNA (ctDNA) is being widely implemented for clinical indications. The sensitivity for …

In clinical oncology, cell-free DNA (cfDNA) has shown immense potential in its ability to
noninvasively detect cancer at various stages and monitor the progression of therapy …